Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Kelley Brant

Nurse Practitioner, Family Murray, UT Nurse Practitioner

NPI 1912641390 CMS profile 11362070

5121 S Cottonwood St, Murray, UT 84107

Open in the dashboard

General payments

$40,104

124 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelley Brant of Murray, UT is reported in the CMS Open Payments database as having received $40,104 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,565 78
2024 General $12,234 41
2023 General $305 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelley Brant
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kelley Brant were reported at $27,565. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kelley Brant Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $0 $141 $44–$430 $149
2023 $305 $154 $49–$476 $160
2024 $12,234 $165 $51–$504 $164
2025 $27,565 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. United Therapeutics Corporation $25,339 78 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $14,062 35 payments
  3. Genzyme Corporation $248 2 payments
  4. AstraZeneca Pharmaceuticals LP $176 3 payments
  5. GlaxoSmithKline, LLC. $133 1 payment
  6. Jazz Pharmaceuticals Inc. $59 1 payment
  7. Verona Pharma, Inc. $54 2 payments
  8. Alexion Pharmaceuticals, Inc. $17 1 payment
  9. Bayer HealthCare Pharmaceuticals Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Consulting Fee $14,379 7 payments
  2. Travel and Lodging $10,411 36 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,845 6 payments
  4. Food and Beverage $5,447 74 payments
  5. Education $23 1 payment
Products named General payments · program years 2023–2025
  1. TYVASO Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease $19,360 51 payments
  2. OFEV $5,816 13 payments
  3. DUPIXENT $248 2 payments
  4. AIRSUPRA $149 2 payments
  5. NUCALA $133 1 payment
  6. REMODULIN $97 1 payment
  7. TYVASO Pah $97 1 payment
  8. ORENITRAM $97 1 payment
  9. Steen Solution $68 2 payments
  10. XYWAV $59 1 payment
  11. Other $159 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

814

Median for Nurse Practitioner: 389

Drug cost

$617,835

Median for Nurse Practitioner: $21,885

Branded share of claims

67.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 29 $386,017
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 64 $69,528
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 88 $63,371
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 103 $56,008
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 17 $11,986
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 72 $7,616
Symbicort Budesonide/Formoterol Fumarate Brand 20 $5,636
Advair Hfa Fluticasone Propion/Salmeterol Brand 18 $5,577
Fluticasone-Salmeterol Hfa Fluticasone Propion/Salmeterol Brand 14 $3,856
Albuterol Sulfate Hfa Albuterol Sulfate Brand 103 $2,742

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$11,332

Medicare's payments for the services billed

Medicare patients

102

Average age 75

Services billed

174

50 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
COPD 53%
Arthritis 51%
Ischemic heart disease 46%
Diabetes 31%
Chronic kidney disease 30%
Heart failure 27%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $5,816
$5,816 29 —
TYVASO
  • United Therapeutics Corporation $4,570
$4,570 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $138
$138 — —
NUCALA
  • GlaxoSmithKline, LLC. $133
$133 — —
Adempas
  • Bayer HealthCare Pharmaceuticals Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record